Kira’s KP-301 was separately licensed to Mirador for $12 million upfront, while Jasper said the merger and financing extend cash runway into the second half of 2028 and support multiple clinical milestones.
Jasper Therapeutics said it completed its all-stock acquisition of Kira Pharmaceuticals and signed a private placement expected to raise about $132 million in gross proceeds, while Kira separately licensed KP-301 to Mirador Therapeutics for $12 million upfront plus potential development and sales milestones. Jasper said the combined company will remain listed on Nasdaq as JSPR and that cash at closing, including financing and out-licensing proceeds but excluding milestones, should fund operations into the second half of 2028. Mirador said KP-301, a potentially long-acting anti-C5a antibody, will initially be developed for ANCA-associated vasculitis, with Phase 1 planned by year-end 2026 and a Phase 2 study in the first half of 2027.